Dean Richard Artis net worth and biography

Dean Artis Biography and Net Worth

EVP of Annexon

Dr. Artis joined Annexon as CSO in January 2023. Dr. Artis most recently served as CSO at Octant Bio and earlier, he served as Senior Vice President, Chemistry at Annexon where he led the efforts on small molecule classical complement inhibitors that resulted in the nomination of ANX1502 as a development candidate. He previously served as Senior Vice President, Research at Elan Pharmaceuticals, Vice President, Lead Generation at Plexxikon and held positions of increasing responsibility at Genentech and Syntex. He has co-authored over 45 papers, been recognized as a co-inventor on 45 issued U.S. patents and made direct contributions to seven molecules that have reached various stages of clinical development, including two that have received marketing approval. He received a B.S. in chemistry from the University of California, Berkeley, and a Ph.D. in organic chemistry from Yale University.

What is Dean Richard Artis' net worth?: The estimated net worth of Dean Richard Artis is at least $376.32 thousand as of February 18th, 2025. Artis owns 83,814 shares of Annexon stock worth more than $376,325 as of December 5th. This net worth evaluation does not reflect any other assets that Artis may own. Additionally, Artis receives an annual salary of $797,380.00 as EVP at Annexon. Learn More about Dean Richard Artis' net worth.
How old is Dean Richard Artis?: Artis is currently 63 years old. There are 5 older executives and no younger executives at Annexon. The oldest executive at Annexon is Dr. Ted Yednock Ph.D., Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board, who is 66 years old. Learn More on Dean Richard Artis' age.
What is Dean Richard Artis' salary?: As the EVP of Annexon, Inc., Artis earns $797,380.00 per year. The highest earning executive at Annexon is Mr. Douglas Love Esq., J.D., CEO, President & Director, who commands a salary of $980,120.00 per year. Learn More on Dean Richard Artis' salary.
How do I contact Dean Richard Artis?: The corporate mailing address for Artis and other Annexon executives is , , . Annexon can also be reached via phone at 650-822-5500 and via email at [email protected]. Learn More on Dean Richard Artis' contact information.
Has Dean Richard Artis been buying or selling shares of Annexon?: Dean Richard Artis has not been actively trading shares of Annexon during the last ninety days. Most recently, Dean Richard Artis sold 5,515 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $2.97, for a transaction totalling $16,379.55. Following the completion of the sale, the executive vice president now directly owns 83,814 shares of the company's stock, valued at $248,927.58. Learn More on Dean Richard Artis' trading history.
Who are Annexon's active insiders?: Annexon's insider roster includes Dean Artis (EVP), William Carson (Director), Jamie Dananberg (Insider), Sanjay Keswani (EVP), Jennifer Lew (CFO), Douglas Love (CEO), Michael Overdorf (EVP), Muneer Satter (Director), and Ted Yednock (EVP). Learn More on Annexon's active insiders.
Are insiders buying or selling shares of Annexon?: During the last twelve months, Annexon insiders bought shares 10 times. They purchased a total of 1,876,188 shares worth more than $7,268,165.34. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 32,352 shares worth more than $93,274.67. The most recent insider tranaction occured on December, 1st when Director Jung Choi bought 33,000 shares worth more than $138,270.00. Insiders at Annexon own 11.9% of the company. Learn More about insider trades at Annexon.
Information on this page was last updated on 12/1/2025.

Dean Richard Artis Insider Trading History at Annexon

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/18/2025	Sell	5,515	$2.97	$16,379.55	83,814

Dean Richard Artis Buying and Selling Activity at Annexon

Annexon Company Overview

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Today's Range

Now: $4.49

$4.25

$4.55

50 Day Range

MA: $3.38

$2.68

$4.51

2 Week Range

Now: $4.49

$1.28

$5.66

Volume

2,488,278 shs

Average Volume

3,148,846 shs

Market Capitalization

$537.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Dean Artis Biography and Net Worth

What is Dean Richard Artis' net worth?

How old is Dean Richard Artis?

What is Dean Richard Artis' salary?

How do I contact Dean Richard Artis?

Has Dean Richard Artis been buying or selling shares of Annexon?

Who are Annexon's active insiders?

Are insiders buying or selling shares of Annexon?